A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women.
Phase of Trial: Phase III
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Female genital diseases; Human papillomavirus infections
- Focus Registrational; Therapeutic Use
- 09 Dec 2016 Status changed from active, no longer recruiting to completed.
- 14 Jul 2016 Planned End Date changed from 1 Feb 2017 to 1 Nov 2016.
- 08 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017.